ideasIdea

Public co-investment in first-in-class phase 1 with a royalty return

A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.

A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (novel target or novel mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.

Hypothesis

Public co-investment reduces the first-in-class discount in private financing (the gap in valuation and time to raise between novel and follow-on assets) measurably within five years and yields a portfolio return that covers the fund's costs within fifteen.

Rationale

CPRIT has committed billions with a documented multiplier in private follow-on investment and company relocation; CIRM funded therapies now in late-stage trials. Public capital is patient and can accept the higher failure rate of novelty in exchange for a share of rare large wins.

What would test it

Capitalise a fund at $500 million, invest only in assets passing an independent first-in-class test, and compare private follow-on financing and time-to-phase-2 of funded assets against matched unfunded novel assets after five years.

Maturity

speculative

Who has to act

policy

Cost to try

Large (over $50M)

Years to first evidence

Bottlenecks it attacks

Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.

Connected

5top

ideas

A diversified royalty pool that finances academic phase 1 trials across fifty assets A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks Government reinsurance for phase 2 failures of first-in-class cancer drugs

bottlenecks

Incentives reward me-too drugs and marginal gains The valley of death between lab and product